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Summary
The expression and function of a receptor tyrosine kinase, c-kit, in the adult bone marrow of
the mouse were investigated by using monoclonal antibodies (mAbs) against the extracellular
domain of murine c-kit. In adult C57BL/6 mouse, 7.8% of total bone marrow cells express
c-kit on their surface. Half of the c-kit+ cells do not express lineage markers including Mac-1,
Gr-1, TER-119, and B220, while the remainder coexpress myeloid lineage markers such as Mac-1
and Gr-1. After c-kit+ cells were removed from the bone marrow cell preparation, hemopoietic
progenitor cells reactive to IL3, GM-CSF, or M-CSF and also those which give rise to spleen
colonies in irradiatedrecipients disappeared almost completely. Thus, most hemopoietic progenitors
in the adult bone marrow express c-kit. To investigate whether or not c-kit has any role in the
hemopoiesis of adult bone marrow, we took the advantage of one of the anti-c-kit mAbs that
can antagonize the function of c-kit. As early as two days after the injection of 1 milligram
of an antagonistic antibody, ACK2, almost all hemopoietic progenitor cells disappeared from
the bone marrow, which eventually resulted in the absence of mature myeloid and erythroid
cells in the bone marrow. These results provide direct evidence that c-kit is an essential molecule
for constitutive intramarrow hemopoiesis, especiallyfor the self-renewal of hemopoietic progenitor
cells at various stages of differentiation.
T
he protooncogene c-kit encodes a receptor tyrosine ki-
nase belonging to the platelet derived growth factor
(PDGF)t/CSF-1 receptor subfamily (1). Recent studies have
shown that c-kit is allelic with the dominant spotting locus
(W) of mice (2, 3). Since mice homozygous with the W al-
lele which encodes a nonfunctional c-kit gene product die
perinatally of severe anemia (4), it is clear that c-kit and its
ligand play an essential role in intramarrow hemopoiesis in
the adult mouse. More recently, a gene encoding the ligand
for c-kit was cloned by several groups (5-9) . This ligand was
demonstrated to have colony stimulating activity ofmultipo-
tent progenitors (9-11). Thus far, this newest hemopoietic
growth factor and CSF-1 are the only two factors whose ac-
tual roles in vivo are well understood, owing to the avail-
ability of the mice which are defective in these genes (12-14).
'Abbreviations used in this paper. APC, allophycocyanin; CFC, colony-
forming cell; GM-CSF, granulocyte macrophage colony-stimulating factor;
PDGF, platelet-derived growth factor.
63 J. Exp. Med. © The Rockefeller
Volume 174 July 1991 63-71
Despite the considerable understanding of the essential role
of c-kit and its ligand on the regulation of constitutive
hemopoiesis in adult bone marrow (15, 16), several questions
remain to be resolved. First, it is not clear which types of
intramarrow hemopoietic cells express c-kit, although expres-
sion of c-kiton the surface ofmast cells has been clearly shown
(17). To closely examine the expression ofc-kit in bone marrow
cells, it is necessary to produce mAbs against the extracel-
lular domain ofc-kit. Secondly, recent studies have suggested
that multipotent stem cells, erythroid progenitors and some
B lineage progenitors can be stimulated to form colonies in
vitro by the recombinant c-kit ligand (5, 9-11). However,
this does not necessarily mean that the maintenance of these
progenitor cells in the bone marrow is actually dependent
on c-kit. If a mAb which can antagonizethe function ofc-kit
is obtained, an in vivo blocking experiment may resolve this
question. This kind of experiment is important for such a
molecule as c-kitwhose expression does not necessarily indi-
cate that it is functioning. For example, although c-kit has
University Press - 0022-1007/91/07/0063/09 $2.00been shown to be expressed in the brain (3, 18), develop-
ment ofthe central nervous system appears to be normal even
in the W/ W mouse, which does not express functional c-kit
at all.
Recently, we developed mAbs against the extracellular do-
main of c-kit, some of which can block the function of c-kit
both in vitro and in vivo (46). An antagonistic anti-c-kitmAb
injected into pregnant mice couldbe transported to the em-
bryo through the placenta, and was able to block the coloni-
zation of melanocyte precursors into the epidermal layer of
the skin, thereby producing unpigmented offspring from a
pigmented mouse. In the present study, we used these anti-
c-kit mAbs and attempted to determine the expression and
function of c-kit in hemopoietic cell progenitors. Our results
demonstrate that c-kit is expressed on almost all hemopoietic
cell progenitors clonable in vitro by various soluble hemo-
poietic growth factors and on most spleen colony-forming
cells (CFCs). We also show that this receptor molecule actu-
ally functions in these cells in vivo.
Materials and Methods
Mice.
￿
C57BL/6 mice and WB-W/+ micewere purchased from
Japan SLC Inc. (Shizuoka, Japan). WB-WI W andWB-+/+ mice
were obtained by mating of WB-W/+ parents.
MonoclonalAntibodiesand Cell Staining.
￿
Anti-B220 (RA3-6B2)
(19), anti-pb (MB86) (20), Mac-1 (M1/70) (21), Gr-1 (granulocyte
lineage marker, RB6-8C5) (22), anti-CD4 (GK1.5) (23), anti-CD8
(53-6.72) (24), and TER-119 (erythroid lineage marker) (25) were
used. The hybrrdomms producing anti-c-kitmAbs, ACK2 (IgG2b)
and ACK4(IgG2a), were established from a rat immunized with
IL3-dependent normal mast cells as follows. 11,3-dependent mast
cells were established from bone marrow cells of WB-+/+ and
WB-WIW neonates as described by Nakano et al. (26) except that
we used recombinant IL3 instead ofPWM-stimulated spleen cell
conditioned medium. Twenty million cultured mast cells derived
from a normal littermate were injected intravenously twice into
a Wistar rat and then spleen cells were prepared for the fusion with
the X63.653.Ag8 (20). Antibody-producing hybridoma clones were
selected on the basisof binding to normal but not W/W mouse-
derived I1,3-dependent mast cells. Although these two mAbs recog-
nize the extracellular domain of c-kit, ACK2 but not ACK4 can
block blood cell formation in long-term bone marrow culture. All
mAbs were used as the hybridoma supernatants or as the purified
antibodies conjugated with FITC or allophycocyanin (APC) for
cell staining. In the case of hybridoma supernatant, the stained cells
were developed with the FITC-conjugated anti-rat k (MAR18.5)
(27) as a second antibody. Cells were analyzed by Epics Profile
(Coulter Electronics Inc., Hialeah, FL) or FACStarP'°'® (Becton-
Dickinson Immunocytometry Systems, SanJose, CA) as described
(28, 29).
Antibody Injection.
￿
B6 male mice were injected with 100 ug
or 1 mg purified antibodies intravenously every other day. Mice
were then anesthetized and sacrificed by cervical dislocation, and
bone marrow cells were analyzed for lineage markers and colony
forming ability.
Cytokines.
￿
Murine recombinant 111,3, GM-CSF, and IL7 were
prepared and titrated as described previously (28, 30). 20 U/ml of
IL7, 200 U/ml of IL3, 100 U/ml of GM-CSF, or 10% of L cell-
conditioned medium as the source ofM-CSF/CSF-1 (14) were used
for the colony assay.
64 Function of c-kit in Intramarrow Hemopoiesis
Colony Assay.
￿
Methylcellulose culture was performed as de-
scribed (30). Briefly, 2 x 10^ bone marrow cells were incubated
in 1 ml of culture medium containing tx-MEM (Gibco Laborato-
ries, Grand Island, NY), 1.2% methylcellulose (Methocel AAM;
Muromachi Kagaku Kogyo, Tokyo, Japan), 30% FCS (HyClone,
Lot No. 1115741; HyClone Laboratories Inc., Logan, UT), 1%
deionized BSA (Sigma Chemical Co., St. Louis, MO), 50 AM 2-ME
and cytokines. On the seventh day ofculture, aggregatesconsisting
of >40 cells were scored as a colony.
Colonrforming Unit-S (CFU-S) Assay.
￿
Female B6 mice were
X-irradiated (9 Gy). After 24 h, the mice were injected intrave-
nously with 5 x 10^ or 2.5 x 105 cells suspended in Eagle's
MEM. Mice were anesthetized and sacrificed by cervical disloca-
tion at 8 or 13 d after injection (31, 32). The spleens were removed
and fixed in formalin/acetic acid/alcohol and colonies were counted.
Controls injected with cell-free suspending medium had 2 colo-
nies per 13 spleens.
Depletion ofc-kit* Cellsfrom Bone Marrow Preparation.
￿
Ten mil-
lion bone marrow cells harvested from normal B6 mice were in-
cubated with ACK4 or RA3-6B2, and resuspended in 1 ml ofEagle's
MEM supplemented with 5% FCS. The paramagnetic microspheres
coated with sheep anti-rat IgG (Dynabeads M-450; Dynal, Oslo,
Norway) (33) were washed and suspended with same medium at
the concentration of4 x 108 beads/ml. One ml of the beads sus-
pension was mixed with the cell suspension prepared above and
incubated on ice for 30 min with gentle shaking. The mixture was
then diluted 1:5 by adding medium. The beads were removed twice
by a magnetic concentrator (MPC1; Dynal) together with the cells
bound to the beads. The cell recoveries were always around 30%.
An aliquot of the remaining negative cells was stained again with
the corresponding antibody and checked by flow cytometry. The
remainder was tested in the colony assay described above.
Results
Establishment ofAnti-c-kit Monoclonal Antibody.
￿
IL-3-de-
pendent mast cells derived from normal mouse bone marrow
highly express the c-kit gene and are able to proliferate in
the presence of the ligand of c-kit without the addition of
IL3 (5, 6, 10, 16). On the other hand, mast cells derived
from W/ W mice produce a c-kit molecule from which the
transmembrane domain is deleted (4, 34). Consequently, the
cells are expected to fail to express c-kit on the cell surfaces.
This fact prompted us to make anti-c-kit mAbs by immunizing
a rat with 11,3-dependent normal mast cells followed by se-
lection on the basis of the ability to bind with the mast cells
derived from a normal littermate mouse but not from a WI W
mouse. By these criteria we obtained four independent mAbs
against c-kit. Fig. 1 shows the surface staining of mast cells
from both a normal and W/W mouse by two of the ob-
tained mAbs, designated ACK2 and ACK4. These two mAbs
recognized normal mast cells while they could not bind to
mast cells derived from the W/W mouse. ACK2 recognized
surface molecules whose mol wt were 120 and 160 kD as
determinedby Western blotting analysis of normal mast cells
(data not shown). These sizes are in good accordance with
those ofc-kit (18). Furthermore, ACK2 bound to the COS7
cells transfected with the c-kitcDNA which was cloned into
an expression vector while the parent cells were ACK2 -
(data not shown). These data indicate that the ACK mAbs
specifically bind to the extracellular domain of c-kit.ACK 2
￿
ACK 4
log fluorescence intensity
wrw
Figure 1 .
￿
Surface staining of11,3-dependent mast cells with anti-c-kit
mAbs analyzedby flowcytometry . Mast cells were established from W/W
and +/+ littermates. Histograms of the cells stained byACK2 andACK4
are shown by the thick lines. The thin lines indicate the control staining
by anti-CD4 mAb.
Expression ofc-kit in Bone Marrow.
￿
By using the anti-c-kit
mAb, ACK2, the expression ofc-kit and other lineage markers
in fresh bone marrow cells from adult C57BL/6 mouse was
determined . As shown in Fig. 2, c-kit bright and dull popu-
lations coexist in bonemarrow. The c-kit bright population
Figure 2 .
￿
Expression of c-kit and lineage markers on B6 bone marrow cells. Cells were incubated with normal rat serum, then APC-conjugated
anti-c-kit (ACK2) and FITC-conjugated anti-13220, Gr-1, Mac-1, or TER-119 antibody were added . A mixture of FITC-conjugated anti-13220, Gr-1,
Mac-1, anti-CD4, and anti-CD8 antibodies were used to stain lineage markers (Lin .) positive cells . As a control, APC-conjugated mAbs against irrelevant
antigens were used. Cells were washed, stained with propidium iodide (PI), and analyzed by flowcytometry . The dead cells stained with PI were gated out.
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does not coexpress other lineage markers including 13220,
CD4, CD8, TER-119, Gr=1, nor Mac-1 . This population ac-
counts for about 3.3 ± 0.3% (mean ± SD) ofthe total bone
marrow cells . Most of the c-kit dull population coexpresses
some ofthese lineages markers, although those which coex-
press 13220 orTER119 are extremely low in number. The
dull c-kit staining of Gr-1 and Mac-1 positive cells seems to
be specific, since the addition of isotype matched unrelated
mAb or normal rat serum does not affect this staining (data
not shown) . Thus, total c-kit positive cells account for 7.8%
± 0.6% of total bone marrow cells if the c-kit dull positive
cells are included .
Expression ofc-kit on the Surface of Hemopoietic Progenitor
Cells. Next we investigated whether c-kit is expressed on
the surface ofhemopoietic progenitor cells includingCFU-S .
Normal bone marrow cells were incubated either with anti-
c-kit mAb ACK4 or anti-13220mAb 6B2, and antibody-bound
cells were depleted by using anti-rat Ig antibody-coated mag-
neticbeads . More than90% of the positive cells were depleted
by this treatment (data not shown) . The number of CFC
reactive to 110, GM-CSF, M-CSF, or lIr7 and spleen CFUs
was measured (Table 1) . When c-kit+ cells were removed
from bonemarrow cells, CFU-IIr3, CFU-GM, CFU-M, and
CFU-S were depleted almost completely, while CFU-11,7
remained . Consistent with previous reports (30, 35), deple-' The c-kit* or B220+ cells were depleted from the bone marrow of B6 mouse by using antibody coated magnetic beads. For in vitro CFC assay,
2 x 104 cells were incubated in 1 ml of semisolid medium containing various cytokines for 7 d and aggregates consisting of 40 or more cells were
scored as a colony. For the CFU-S assay, 5 x 104 cells from control or B220+-depleted sample, or 2.5 x 105 cells from ACK4*-depleted sample
were injected into an irradiated mouse. The spleen was removed and fixed 8 d after injection and number of colonies was counted.
t Mean ± SD for triplicates.
tion of B220+ cells removed CFU-IL7 completely, while
other CFCs and CFU-S remained intact. This result clearly
indicates that c-kit is expressed on the surface ofall hemopoietic
progenitors, including CFU-1173, CFU-GM, CFU-M, and
CFU-S, except CFU-11177 of the B cell lineage.
Induction of Anemia by ACK2 Injection.
￿
The results de-
scribed in the preceding sections demonstrated the expres-
sion of c-kit on the surface of hemopoietic progenitor cells.
However, it remained to be elucidated whether c-kit is func-
tionally required for these progenitor cells in vivo. To ad-
dress this question, we took advantage of an antagonistic
anti-c-kitmAb, ACK2, which was shown to block the func-
tion of c-kit but not to be cytotoxic to c-kit' cells (46). If
c-kit on the surface of hemopoietic progenitor cells is func-
tioning in vivo, administration of ACK2 would induce se-
vere anemia. In fact, ACK2 inhibited myelopoiesis in a long-
term bone marrow culture with a stromal cell clone (our
unpublished observation) .
One milligram of purified ACK2 was injected into B6 mice
intravenously every second day and the number of B220+,
TER-119+, or Mac-1+ cells in bone marrow was measured
on various days after the initiation of ACK2 injection. Purified
Mac-1 antibody was injected as a class matched control. Fig.
3 shows the morphology of the bone marrow cells from
normal, Mac-l-injected, or ACK2-injected mice 12 d after
the initial injection. No significant difference was observed
between the bone marrow cells from normal and Mac-1 treated
mice. In contrast, no polymorphonuclear cells or erythro-
blasts were present in the bone marrow of an ACK2 injected
mouse, and most of the cells remaining in this bone marrow
showed lymphoid morphology. This observation was con-
firmed by flow cytometry analysis (Fig. 4), which demon-
strated that no Mac-1 + cells nor TER119 * cells were present
in the bone marrow of ACK2-injected mouse and that 90%
of the total cells were B220+ B lineage cells including 16%
of surface IgM+ cells. It is important to note that even after
such a complete depletion ofmyeloid and erythroid cell lineages
from bone marrow, the number of bone marrow cellsrecov-
ered from ACK2-injected mice was nearly normal. This sug-
gests that B lineage cells continued to grow in the ACK2-
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treated mouse to fill the space from which myeloid and
erythroid progenitor cells were purged.
Fig. 5 shows the time course of the changes in the content
of each type of lineage marker positive cells after the initia-
tion of ACK2 injection. The proportions of Mac-1+ my-
eloid cells and B220+ B lymphocytes did not change sig-
nificantly by 4 d after the initiation of ACK2 injection.
Mac-1 + cells then decreased abruptly during the next 4 d.
B220+ cells increased in parallel with the decrease in Mac-1+
cells. Although the number of total nucleated cells decreased
to half the normal level during the initial 8 d along with
the decrease in Mac-1+ cells, it then returned to the control
level by the overgrowth of B220+ cells (data not shown).
The number of TER-119+ erythroid lineage cells decreased
more rapidly than Mac-l' cells.
Rapid Elimination ofHemopoietic Progenitor Cells by ACK2
Injection. The results in the preceding section demonstrated
that ACK2 injected into adult mouse couldeliminate lineage
marker positive mature myeloid and erythroid cells, while
leaving the B lineage cell compartment intact. Next, we in-
vestigated the effect of ACK2 on the progenitor cells of my-
eloid and B cell lineages which can generate in vitro colonies
in response to various hemopoietic growth factors. The same
bone marrow cells from ACK2-treated mice used in the ex-
periments in the previous section were analyzed for the pres-
ence of CFCs reactive to IL-3, GM-CSF, M-CSF, and IL-7.
As shown in Fig. 6, CFU-IL3, CFU-GM, and CFU-M dis-
appeared from the bone marrow much earlier than mature
myeloid cells did, and a single ACK2 injection eliminated
these CFCs almost completely. On the other hand, the number
of CFU-IL7 increased five- to six-fold, suggesting that ac-
tive proliferation of B cell precursors was actually induced
in ACK2-treated bone marrow. Because the addition ofACK2
did not affect the formation of colonies from normal bone
marrow cells in semisolid medium containing various cyto-
kines, the disappearance of CFC was not due to a cytostatic
effect of ACK2 during the culture assay period (data not
shown).
Furthermore, it is important to note that CFU-IL3, CFU-
GM, and CFU-M decreased simultaneously rather than in
Table 1 . Depletion of c-kit` Cells Eliminates Hemopoietic Progenitors from Bone Marrow of B6 Mice
Bone marrow
No. of CFU/105 cellst
cells" CFU-S CFU-IL-3 CFU-GM CFU-M CFU-IL-7
Control 18.0 ± 6.0 616.7 ± 44.3 403.4 ± 31 .0 326.7 ± 15.2 93.3 ± 2.9
c-kit'-depleted 0.2 ± 0.2 15.0 ± 10.0 20.0 ± 8 .7 3.3 ± 5 .8 78.3 ± 11 .5
B220+-depleted 20.0 ± 5 .5 818.4 ± 59.1 548.4 ± 34.5 476.7 ± 49.3 5 .0 ± 5.0Figure 3 .
￿
Morphology of the cells in the bone marrow of the mice ad-
ministrated with antibodies. Cytospots were prepared from the bone marrow
cells of a normal B6 mouse (A), a mouse given 6 shots of 1 mg ACK2
(B) or Mac-1 (C) on alternate days, and stained with May-Gruenwald-
Giemsa solution . Scale bars indicate 20 gm.
order of the proposed differentiation hierarchy of these pro-
genitor cells (36, 37) . This suggests that c-kit is functionally
required for the maintenance of all of these CFCs in vivo.
To further investigate whether or not eachCFC has a different
sensitivity to ACK2 treatment, the dose of ACK2 was de-
creased to 100 Ag and the numbers ofCFCs were measured .
The sensitivity of each CFC to ACK2 as estimated from Table
2 seemed not to differ significantly. Although only incom-
plete reduction of each CFC was induced by 10014g ACK2
in the bone marrow, the magnitude ofreduction did not differ
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Figure 4 .
￿
Flow cytometric analysis ofthe bone marrow cells of an anti-
c-kit antibody-treated mouse. Bone marrow cells harvested from a control
mouse (A) or a mouse given 6 shots of 1 mg ACK2 (B) were stained with
anti-B220, Mac-1, or TER-119. % positive cells estimated from the profiles
are shown in Fig. 5 (Day 12) .
significantly. We have also previously observed that 100 Ag
is the dose at which adult spermatogenesis is completely
blocked in vivo (Yoshinaga, K., S . Nishikawa, M . Ogawa,
S .I . Hayashi, T . Kunisada, T. Fujimoto, and S .I . Nishikawa,
manuscript submitted for publication) . Thus, the sensitivi-
ties to ACK2 seem to vary among c-kit-dependent tissues.
Elimination ofColonyforming Units-S (CFU-S) byACK27n-
jection . Finally, we investigated whether the earliest hemo-
poietic progenitor cellswhich can give rise to spleen colonies
upon transfer into lethally irradiated recipients are dependent
on c-kit in vivo (38) . Bonemarrow cells were harvested from
mice which had been given 6 i.v. shots of 1 mg mAb, and
the number ofCFU-S was determined (Table 3) . Again, most
ofCFU-S were depleted from the bone marrow ofACK2-
injected mouse irrespective of the day of the assay for spleen
colony (31, 32) . Interestingly, small but a significant number
of day 13 CFU-S (approximately 10% of control) always re-
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￿
Effects of anti-c-kit antibody injection on the content ofbone
marrow cells . B6 mice were injected 1 mg ACK2 every other day and
the content ofeach lineage marker* cells in bone marrow was analyzed
as shown in Fig. 4 .mained in the bone marrow, and these colonies were large
mixed type colonies (Fig. 7) . Therefore, a small fraction of
day 13 CFU-S is resistant to the antagonistic activity of the
anti-c-kit antibody.
Discussion
The major aim of the present study was to characterize
the c-kit+ cells in adult mouse bone marrow and also to elu-
cidate thefunctional role of this receptor tyrosine kinase mol-
ecule in this cell population . For this purpose, we used two
mAbs against the extracellular domain of c-kit, ACK2 and
ACK4 . These two mAbs recognize different epitopes on the
c-kit molecule, because binding of one antibody was not
blockedby the other. Moreover, in vitro hemopoiesis onPA6
stromal cell clone (39, 40) or in Dexter's culture (41) was
blocked completely by ACK2 but not by ACK4, suggesting
that the former is antagonistic to c-kit function (our unpub-
lished observation) .
By using these mAbs, we demonstrated the presence of
c-kit+ cells in adult bone marrow. Interestingly, c-kit+ cells
were further subdivided into c-kitbdghl and c-kitd°il popula-
tions, and c-kitbright cells did not coexpress other lineage
Table 3 .
￿
Effects of Antibody Administration on Colonyforming
Unit-S (CFU-S) in the Bone Marrow ofB6 Mice
B6 mice were given 6 shots of 1 mg antibodies on every other day .
50,000 bone marrow cells from the control mouse or Mac-1 treated mouse,
or 2.5 x 105 bone marrow cells of ACK2 treated mousewere injected
into irradiated recipients . The spleens were removed and fixed 8 or 13 d
after the injection and the number of colonies was counted .
t Mean ± SD for quadruplicates .
S Not done.
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> 150
' B6 mice were given 2 shots of 0.1 or 1 mg ACK2 on alternate days . The number of CFCs in bone marrow was determined as described in the
legend for Table 1 .
t Mean ± SD for triplicates .
Days
--^0 - IL-7
-0-- IL-3
-f--- GM-CSF
-o-- M-CSF
Figure 6 .
￿
Effects of anti-c-kit antibody injection on the numberof CFCs
responding to various cytokines in bone marrow. The same cells shown
in Fig. 5 were analyzed for the number of CFU-IL 7, CFU-IL 3, CFU-
GM, and CFU-M . The number of CFU-11,7 at day 8 and day 12 (%
control) are shown in parentheses since the values are out of scale .
Figure 7 .
￿
Elimination of CFU-S from the bone marrow of an anti-
c-kit antibody-injected mouse. The bone marrow cells of the B6 mouse
given 6 shots of1 mgACK2 on alternate days were analyzed for the number
of CFU-S as described in the legend for Table3 . Note that five-fold larger
number of cells was injected into the recipients in the case ofthe ACK2-
treated mouse .
Table 2. Effects
Treatment"
ofACK2 Administration on
CFU-IL-7
Colony Forming Cells (CFCs) in the Bone
No . of CFC/105
CFU-IL-3
Marrow of B6 Mice
cells$
CFU-GM CFU-M
Control 188 .3 ± 20.2 485.0 ± 34.6 358 .3 ± 41 .3 268.3 ± 29.3
ACK2 (0.1 mg) 335 .0 ± 43 .3 100.0 ± 25.9 125.0±11.9 66.6±8.1
ACK2 (1 mg) 228.3 ± 10.4 6.7 ± 2 .9 16 .7 ± 7.6 3 .3 ± 5.8
Antibody"
No . of CFU-S/10 5
Day 8
cells$
Day 13
Control 19.3 ± 3.1 11.7 ± 2 .3
ACK2 0 .4 ± 0.4 1.5 ± 0.4
Mac-1 20.0 ± 6.0 NDSmarkers while most of the c-kits°u population expressed my-
eloid markers such as Gr-1 and Mac-1. Probably, a small frac-
tion of c-kitd°11 cells coexpressed B220, but no TER-119+
cells were included in this population. This staining pattern
indicates that c-kit is highly expressed in the lineage marker
negative (lin -) immature cell population and that c-kit ex-
pression decreases upon maturation into lin+ cells, although
low level expression continues for some time. Since Willer-
Sieburg et al. have shown that all CFCs were present in the
lin- population (42), c-kitd"11, lin+ population might have
lost the progenitor activity. To confirm this, we are currently
trying to sort each population to estimate the stem cell ac-
tivity. In fact, a recent preliminary result suggests that CFU-S
was highly enriched in a c-kitb6ght, Thy-1duu, lin - popula-
tion (Okada, S., H. Nakauchi, K. Nagayoshi, S. Nishikawa,
S.I. Nishikawa, Y Miura, and T. Suda, manuscript submitted
for publication). Our present result clearly indicated that al-
most all hemopoietic progenitor cells including CFCs reac-
tive to IL3, GM-CSF, or M-CSF and also CFU-S expressed
c-kiton the cell surface, but B lineage progenitors which form
colonies in response to IL-7 were c-kit- . Thus, we expect
that c-kit expression would be additional and powerful markers
in order to purify hemopoietic stem cells in various differen-
tiation stages.
Since most of hemopoietic progenitors expressed c-kit, the
next issue to be resolved was whether or not c-kit on the
surface of these hemopoietic progenitors is functioning in
vivo. The fact that the W1W homozygous mouse has no con-
stitutive hemopoiesis in postnatal life indicates that c-kit is
functioning at least in some progenitor cells (15). Previously,
it was reported that CFCs do exist in the W1 W° mouse
while CFU-S is absent (43) . This may well suggest that c-kit
is functionally required only for the most immature progen-
itors, although it is expressed in both CFC and CFU-S. To
address this question, we took advantage of a mAb capable
of antagonistically blocking the function of c-kit. Injection
of this antibody resulted in a complete and simultaneous elimi-
nation of all hemopoietic progenitor cells including CFU-S
and CFCs reactive to IL3, GM-CSF or even M-CSF which
has been considered to be a growth factor for the precursor
restricted to the macrophage lineage. It could be that ACK2
is cytotoxic antibody eliminating all c-kit+ cells, thereby
depleting all types of hemopoietic progenitors that express
c-kit. We think, however, that this possibility is unlikely for
the following reasons. First, although peritoneal mast cells
highly express c-kit, i.p. injection of ACK2 does not affect
the number ofmast cellsin the peritoneal cavity (our unpub-
lished observation) . Second, although all melanocytes in the
adult hair follicle express c-kit, only those in the activated
hair follicles are affected by ACK2 injection, suggesting that
only c-kit function is blocked by this treatment (46). Third,
although both spermatogonia and oocytes express c-kit, ACK2
injection blocked only spermatogenesis. Fourth, although
Mac-1 used as a class matched control antibody also binds
to myeloid cells, hemopoiesis in Mac-l-treated mice was
normal. Lastly, rat mAbs of IgG2b class against various cell
surface molecules have been used as antagonistic blockers of
molecular interaction on the cell surface, and all previous results
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unequivocally indicated that rat-IgG2b mAb was cytostatic
rather than cytotoxic (44).
It could also be that ACK2 enhances the differentiation
of the progenitor cells, thereby resulting in a depletion of
stem cells. We think this possibility is also unlikely, because
overgrowth of lineage marker bearing mature cells was never
detected at any point after the injection of ACK2. Further-
more, despite extensive trials, we failed to detect any ligand
mimicking activity of ACK2 to induce in vitro differentia-
tion or proliferation of hemopoietic progenitors. On the other
hand, the recombinant ligand for c-kit has recently been
reported to have obvious in vitro activity to induce the prolifer-
ation of various hemopoietic precursor cells (5, 9-11) .
Consequently, it is very likely that ACK2 acts as an an-
tagonistic antibody to c-kitfunction, although it remains to
be elucidated whether ACK2 directly prevents the binding
of the ligand to c-kit. Given that this is the case, our result
must be interpreted as indicating that maintenance of
hemopoietic progenitors in adult bone marrow is dependent
on c-kit and its ligand. Because recent studies demonstrated
that a recombinant ligand for c-kitinduced colonies consisting
of multiple cell lineages (9-11), the abolition ofall CFCs from
ACK2-treated bone marrow may be due to the blockade of
recruitment of lineage restricted progenitors from multipo-
tent stem cells. However, it is important to note that all CFCs
from those reactive to multi-CSF to even M-CSF disappeared
from bone marrow simultaneously. If c-kitis functionally re-
quired for the maintenance of multipotent hemopoietic pro-
genitor cells giving rise to lineage restricted progenitor cells
such as CFU-M, there must be a time lag between disap-
pearance of progenitors reactive to multi-CSF and to M-CSR
In this context, it is interesting that the ligand for c-kit is
able to cooperate with any ofother hemopoietic growth factors
and enhances the number and size ofcolonies induced in bone
marrow cells (10, 11). These results in conjunction with our
present result imply that the maintenance of both multipo-
tent and lineage restrictedhemopoietic progenitor cells is in
fact dependent on c-kit, although some other factors may also
be required.
In contrast to the c-kitdependency ofmyeloid and erythroid
progenitors, B lymphopoiesis was not significantly affected
by ACK2 injection. More interestingly, a subset ofB lineage
cellsdid overgrow to fill the bone marrow space from which
other cell lineages were purged. On the other hand, it was
demonstrated that the ligand for c-kit also remarkably en-
hanced the colony formation of B cell precursors in response
to IL7 (11), suggesting the role of c-kit in intramarrow B
lymphopoiesis. This result, however, is not inconsistent with
our present result, because the previous studies clearly demon-
strated that there is a subpopulation of B lineage cells which
proliferates in response to IL7 alone (28, 30, 35, 45). There-
fore, the population capable of proliferating in response to
IL-7 alone could be the subset that overproliferated in the
ACK2-treated mouse. Alternatively, it could be that there
is another subset ofB lineage precursors which requires yet
unidentified signals for proliferation. Since the ligand for c-kit,
and ACK2 which specifically inhibits the c-kit function are
now available, this issue will be resolved soon.References
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